Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0N9AD
|
|||
| Former ID |
DIB013389
|
|||
| Drug Name |
RNS-60
|
|||
| Indication | Asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Phase 2 | [1] | |
| Multiple sclerosis [ICD-11: 8A40; ICD-9: 340] | Phase 2 | [2] | ||
| Amyotrophic lateral sclerosis [ICD-11: 8B60.0] | Phase 1 | [2] | ||
| Company |
Revalesio Corp
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Heat shock protein 90 (HSP90) | Target Info | Modulator | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01714089) Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of Revalesio. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.